

JCWSCS 15 OCT 2004

OCT. 15. 2004 11:24AM

AVENTIS US PAT DEPT

NO. 8636 P. 1

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages In This Submission

44 pgs.

Application Number

10/760,509

Filing Date

January 20, 2004

First Named Inventor

Stefan PETRY et al.

Art Unit

1645

Examiner Name

Attorney Docket Number

DEAV2003/0003 US NP

**ENCLOSURES (Check all that apply)**

Fee Transmittal Form

☐ Fee Attached

Amendment/Reply

☐ After Final☐ Affidavits/declaration(s)

Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/  
Incomplete Application☐ Reply to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a  
Provisional ApplicationPower of Attorney, Revocation  
Change of Correspondence Address

Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

After Allowance Communication to TC

Appeal Communication to Board  
of Appeals and InterferencesAppeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify  
below):

Request for Corrected Filing Receipt

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

AVENTIS PHARMACEUTICALS INC.

Signature

Printed name

Barbara E. KURYS

Date

October 15, 2004

Reg. No.

34650

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-746-9195); Total No. of Pages Transmitted: 4 pages

Signature

Typed or printed name

Ginnie Walker

Date

October 15, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
DEAV2003/0003 US NP

Examiner:

Art Unit: 1645

Application No.: 10/760,509

Filed: January 20, 2004

Title: **Pyrimido[5,4] [1,2,4] Triazine-5,7-Diones,  
Processes For Preparing Them and Their  
Use**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,  
at (703) 746-9195, on

Date of Transmission

Signature

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in the Applicant(s) it reads: "Karl-Heinz Barimghaus, Wolfersheim, GERMANY" it should be: "Karl-Heinz Baringhaus", Wolfersheim, GERMANY"

The Commissioner is hereby authorized to charge any fees which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,

  
Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0003 US NP



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1459  
Alexandria, Virginia 22313-1459  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/760,509	01/20/2004	1645	900	DEA V2003/0003US NP		11	

005487  
ROSS J. OEHLER  
AVENTIS PHARMACEUTICALS INC.  
ROUTE 202-206  
MAIL CODE: D303A  
BRIDGEWATER, NJ 08807

CONFIRMATION NO. 1471

## UPDATED FILING RECEIPT

\*OC000000013600036\*

COMPUTER ENTERED

8/24/04

Date Mailed: 08/20/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Stefan Petry, Frankfurt, GERMANY;  
Karl-Heinz Barimghaus, Wolfersheim, GERMANY;  
Norbert Tennagels, Frankfurt, GERMANY;  
Guenter Mueller, Sulzbach, GERMANY;

BARINGHAUS

## Assignment For Published Patent Application

Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY;

## Domestic Priority data as claimed by applicant

This appin claims benefit of 60/478,756 06/16/2003

## Foreign Applications

GERMANY 10301788.7-41 01/20/2003

If Required, Foreign Filing License Granted: 04/29/2004

Projected Publication Date: 12/02/2004

Non-Publication Request: No


Early Publication Request: No

**Title**

Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use

## Preliminary Class

435



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

**The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.**

**This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.**

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).